Ocular Therapeutix™ Appoints Michael Goldstein, M.D., M.B.A., as Chief Medical Officer
September 08 2017 - 8:00AM
Business Wire
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical
company focused on the development, manufacturing and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced the appointment of Michael
Goldstein, M.D., M.B.A., as Chief Medical Officer. Dr. Goldstein is
a highly-accomplished ophthalmologist, having held several senior
medical leadership positions with ophthalmology-focused
pharmaceutical companies and published extensively in multiple
ophthalmology scientific journals. In his role, Dr. Goldstein will
oversee the clinical development of the Company’s product
pipeline.
“We are pleased to further strengthen our executive leadership
team with the appointment of Mike as our Chief Medical Officer,”
said Antony Mattessich, Chief Executive Officer. “Mike brings a
deep expertise in both biopharmaceuticals and ophthalmology, and
possesses the vision and clinical leadership skills required to
realize the Ocular’s full potential. His experience will be
critical as we prepare to initiate multiple clinical trials,
including our second Phase 3 trial with OTX-TP for the treatment of
glaucoma and hypertension, our pilot human clinical trial with
OTX-TIC for the treatment of glaucoma and hypertension, and our
Phase 1 clinical trial with OTX-TKI for the treatment of serious
retinal diseases.”
Prior to joining Ocular Therapeutix, Dr. Goldstein served as
Chief Medical Officer of Applied Genetic Technologies Corp (AGTC),
a clinical-stage biotechnology company focused on the development
of products for the treatment of rare diseases, with a focus on
ophthalmology. Before joining AGTC, Dr. Goldstein held several
positions of increasing responsibility with Eleven Biotherapeutics,
including Chief Medical Officer and Vice President of Clinical
Research. Since 2002, Dr. Goldstein has served as Co-Director,
Cornea and External Disease Service and Assistant Professor of
Ophthalmology at the New England Eye Center and Tufts University
School of Medicine. Previously, he was Director of Refractory
Surgery Service and Assistant Professor of Ophthalmology at the
University of Florida College of Medicine. Dr. Goldstein has
published extensively and is a reviewer for multiple ophthalmology
scientific journals. Dr. Goldstein holds an M.D. from Northwestern
University Medical School, an M.B.A. from Northwestern University's
J.L. Kellogg Graduate School of Management, and received his B.A.
in political economy from Williams College.
“I believe Ocular’s hydrogel technology platform offers
tremendous potential to improve patient and physician outcomes
across a wide range of diseases and conditions,” said Dr.
Goldstein. “I look forward to applying my expertise and working
with the team to help ensure the strategic advancement of Ocular’s
diverse portfolio of clinical-stage development programs.”
About Ocular Therapeutix, Inc.Ocular Therapeutix,
Inc. is a biopharmaceutical company focused on the development,
manufacturing and commercialization of innovative therapies for
diseases and conditions of the eye using its proprietary hydrogel
platform technology. Ocular Therapeutix’s lead product candidate,
DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular use,
has completed Phase 3 clinical development for the treatment of
ocular pain and inflammation following ophthalmic surgery. OTX-TP
(travoprost insert) is in Phase 3 clinical development for glaucoma
and ocular hypertension. The Company’s earlier stage assets include
OTX-TIC, a sustained release travoprost intracameral injection for
the treatment of moderate to severe glaucoma and ocular
hypertension, as well as sustained release intravitreal injections
for the treatment of retinal diseases. These injections include the
development of OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in
collaboration with Regeneron, an extended release protein-based
anti-vascular endothelial growth factor (VEGF) trap. Ocular
Therapeutix's first product, ReSure® Sealant, is FDA-approved to
seal corneal incisions following cataract surgery.
Forward Looking StatementsAny statements in this press
release about future expectations, plans and prospects for the
Company including the development and regulatory status of the
Company’s product candidates, such as the Company’s expectations
and plans regarding product development efforts and regulatory
submissions for and the timing and conduct of clinical trials of
DEXTENZA for the treatment of post-surgical ocular inflammation and
pain, including with respect to the manufacturing deficiencies
identified by the FDA and the prospects for approvability of
DEXTENZA for these indications, DEXTENZA for the treatment of
allergic conjunctivitis, DEXTENZA for the treatment of dry eye
disease and OTX-TP for the treatment of glaucoma and ocular
hypertension, the ongoing development of the Company’s sustained
release intravitreal depot, the potential utility of any of the
Company’s product candidates, potential commercialization of the
Company’s product candidates, the sufficiency of the Company’s cash
resources, and other statements containing the words "anticipate,"
"believe," "estimate," "expect," "intend", "goal," "may", "might,"
"plan," "predict," "project," "target," "potential," "will,"
"would," "could," "should," "continue," and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors. Such
forward-looking statements involve substantial risks and
uncertainties that could cause the Company’s clinical development
programs, future results, performance or achievements to differ
significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, those related to the timing and costs involved in
commercializing ReSure® Sealant or any product candidate that
receives regulatory approval, the initiation and conduct of
clinical trials, availability of data from clinical trials and
expectations for regulatory submissions and approvals, the
Company’s manufacturing operations, the Company’s scientific
approach and general development progress, the availability or
commercial potential of the Company’s product candidates, the
availability of cash resources and need for additional financing or
other actions and other factors discussed in the “Risk Factors”
section contained in the Company’s quarterly and annual reports on
file with the Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent
the Company’s views as of the date of this release. The Company
anticipates that subsequent events and developments will cause the
Company’s views to change. However, while the Company may elect to
update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do so.
These forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the
date of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170908005438/en/
InvestorsBurns McClellanSteve Klass,
212-213-0006sklass@burnsmc.comorOcular TherapeutixGeorge
MigauskyInterim Chief Financial
Officergmigausky@ocutx.comorMediaOcular TherapeutixScott
CorningVice President of Marketing & Commercial
Operationsscorning@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Apr 2024 to May 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From May 2023 to May 2024